A new Thirona–COPD Foundation study will assess AI-derived QCT biomarkers in over 10,000 COPDGene participants to support advanced phenotyping and targeted treatment.
Divestment of Thirona Retina BV to continue focus on pulmonary diseases and expanding within the interventional pulmonology space
To achieve our mission of advancing personalized and tailored approaches to lung disease treatment and care, we are welcoming top clinical experts to Thirona's Medical Advisory Board.
Thirona and Free Flow Medical signed a partnership agreement to provide clinicians with advanced high-precision tools for treatment planning.
Thirona BV and Pulmonx Corporation have extended their long-running strategic partnership.
We are proud to inform that we have just closed a financing round with Belgian investment fund HERAN Partners and Borski Fund from the Netherlands.
Thirona is present at the ATS 2019 from 17-22 May in Dallas, TX. Visit our booth #3022 and learn about our lung quantification software based on artificial intelligence.
The paper demonstrates that this latest version of CAD4TB outperforms all previous versions; the software is now operating at the level of expert human readers in detecting TB from chest X-Ray.